Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T-cell immunity

Although many advantageous roles of cisplatin (cis-diamminedichloroplatinum (II), CDDP) have been reported in cancer therapy, the immunomodulatory roles of cisplatin in the phenotypic and functional alterations of dendritic cells (DCs) are poorly understood. Here, we investigated the effect of cispl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Woo Sik, Kim, Hongmin, Kwon, Kee Woong, Im, Sin-Hyeog, Lee, Bo Ryeong, Ha, Sang-Jun, Shin, Sung Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper: Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085117/
https://www.ncbi.nlm.nih.gov/pubmed/27172902
http://dx.doi.org/10.18632/oncotarget.9260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085117/
https://www.ncbi.nlm.nih.gov/pubmed/27172902
http://dx.doi.org/10.18632/oncotarget.9260

Ejemplares similares